At a glance
- Originator Novartis
- Mechanism of Action Chelating agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Iron overload
Most Recent Events
- 18 Jun 1999 New profile
- 18 Jun 1999 Preclinical development for Iron overload in England (Unknown route)